US Court Rules In Favor Of Viatris For Interchangeable Semglee
Partners Biocon and Viatris To Continue To Market Insulin Glargine Biosimilar
Viatris and Biocon continue marketing their recently launched interchangeable biosimilar Semglee (insulin glargine-yfgn) as a US appeals court affirms that the challenged claims of five of Sanofi’s Lantus SoloSTAR device patents are unpatentable.
